Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | EBP | Q15125 | 2/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332177 | 0.92 | ABCB1 (0.60) | ABCB1DRD2DRD4SIGMAR1EBP | |
| SCHEMBL1332640 | 0.88 | ABCB1 (0.55) | ABCB1DRD2DRD4SIGMAR1EBP | |
| SCHEMBL7030738 | 0.87 | SIGMAR1 (0.61) | SIGMAR1EBPTMEM97ADRA1DADRA1A | |
| SCHEMBL1332075 | 0.86 | ABCB1 (0.61) | ABCB1DRD2DRD4SIGMAR1EBP | |
| Hydrochloric Acid SCHEMBL1332727 | 0.86 | SIGMAR1 (0.60) | SIGMAR1EBPTMEM97ADRA1DADRA1A | |
| SCHEMBL1333878 | 0.86 | ABCB1 (0.53) | ABCB1DRD2DRD4SIGMAR1EBP | |
| SCHEMBL1333143 | 0.86 | ABCB1 (0.53) | ABCB1DRD2DRD4SIGMAR1EBP | |
| SCHEMBL1333938 | 0.85 | HTR1A (0.58) | ABCB1DRD2DRD4 | |
| SCHEMBL2157270 | 0.85 | DRD2 (0.55) | DRD2DRD4 | |
| SCHEMBL1333268 | 0.84 | HTR1A (0.55) | ABCB1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | claimed |
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| EP-1978959-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| EP-2340835-A1 | Piperidine and piperazine derivatives | M's Science Corporation (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-2340835-A1 | Piperidine and piperazine derivatives | M's Science Corporation (JP) | 2011-07-06 | — | — | EP | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
| EP-1978959-A4 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2009-09-02 | — | — | EP | disclosed |
| CN-101511187-A | Piperidine and piperazine derivatives | MS SCIENCE CORP (JP) | 2009-08-19 | — | — | CN | disclosed |
| EP-1976525-A4 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2009-07-15 | — | — | EP | disclosed |
| CN-101448503-A | Piperidine and piperazine derivatives | MS SCIENCE CORP (JP) | 2009-06-03 | — | — | CN | disclosed |
| EP-1978959-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES | M's Science Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1976525-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES | M's Science Corporation (JP) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008096189-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES | M'S SCIENCE CORPORATION (JP) | 2008-08-14 | — | — | WO | disclosed |
| WO-2007089462-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES | M'S SCIENCE CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089462-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES | M'S SCIENCE CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SIGMAR1, OPRM1, OPRD1 | ABCB1 486/4885DRD2 28/4885DRD4 66/4885 |
| US-20110281890-A1 | Piperidine and piperazine derivatives | SIGMAR1, OPRM1, OPRD1 | ABCB1 591/4885DRD2 17/4885DRD4 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.